Skip to main content

Table 1 Population characteristics of US adults ≥20 years of age with and without CKD stage 1–4* based on NHANES 2001–2010 survey participants

From: Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010

Characteristic With CKD Without CKD P
  (n=1,428) (n=8,487)  
Age at screening (years) 64.2 (0.7) 44.5 (0.3) <0.001
Male (%) 41.7 (1.5) 49.5 (0.5) <0.001
Race/ethnicity (%)    0.001
  Non-Hispanic white 75.4 (2.1) 71.2 (1.4)  
  Non-Hispanic black 11.6 (1.1) 10.7 (0.8)  
  Mexican American 5.7 (0.9) 8.0 (0.7)  
  Other 7.3 (1.4) 10.1 (0.8)  
eGFR (mL/min/1.73 m2) 68.4 (1.0) 97.9 (0.4) <0.001
Body mass index (kg/m2) 29.7 (0.3) 28.2 (0.1) <0.001
  (n=1,372) (n=8,398)  
Blood pressure (mmHg)    
  Systolic 133.2 (0.8) 119.4 (0.2) <0.001
  Diastolic 67.5 (0.6) 70.2 (0.2) <0.001
Lipids (mg/dL)    
  Total cholesterol 194.3 (1.4) 196.4 (0.6) 0.1
  LDL-C 111.4 (1.1) 117.6 (0.5) <0.001
  HDL-C 54.4(0.5) 54.0 (0.2) 0.6
  Triglycerides 142.6 (2.4) 124.2 (1.0) <0.001
Antidiabetic medication use (%)ठ21.0 (1.4) 4.8 (0.2) <0.001
  1. Values are weighted estimates presented as percent (standard error) or mean (standard error). Estimates were standardized to the July 2008 US census population ≥20 years of age. Conversion factors for units: eGFR in mL/min/1.73 m2 to mL/s/1.73 m2, ×0.01667; total cholesterol, LDL-C and HDL-C in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129; glucose in mg/dL to mmol/L, ×0.05551.
  2. *CKD Stage 1–4 was identified by the presence of kidney damage (based on albuminuria) and level of decline in kidney function (based on eGFR), and staged using modified National Kidney Foundation criteria (see Methods).
  3. P values are for with versus without CKD; P value for race/ethnicity compares the distribution of race/ethnicity categories. Rao-Scott chi-square P values for categorical variables were obtained using the SAS procedure SURVEYFREQ; between-cohort P values for continuous variables were obtained using the SAS procedure SURVEYREG (see Methods).
  4. ‡All drug utilization was self-reported.
  5. §Any antidiabetic agents including insulin and oral medications for diabetes.